XML 56 R44.htm IDEA: XBRL DOCUMENT v3.21.2
Collaborative and Licensing Agreements - Additional Information (Detail) - USD ($)
1 Months Ended 6 Months Ended
Nov. 30, 2018
Jun. 30, 2021
Endo Pharmaceuticals Inc [Member]    
Royalty terms   first commercial sale of the product in that country and extends until the later of the expiration, unenforceability or invalidation of the last valid claim of any licensed patent or application covering the licensed product in the country or the expiration of 10 years after the first commercial sale of the licensed product in the country, which period is referred to as the royalty term. Upon the expiration of the royalty term for a product in a country
Endo Pharmaceuticals Inc [Member] | Completion Of Stage One [Member]    
Milestone payments to be paid   $ 300
Endo Pharmaceuticals Inc [Member] | Completion Of Stage Two [Member]    
Milestone payments to be paid   800
Rutgers [Member]    
Milestone payments to be paid   $ 300
Royalty terms   first commercial sale of the licensed product in that country following receipt of marketing approval and extends until the later of the date of expiration, unenforceability or invalidation of the last valid claim of any licensed patent or patent application covering the licensed product in the country and 10 years after the first commercial sale of the first licensed product sold anywhere in the world, which period is referred to as the royalty term. Upon the expiration of the royalty term for a licensed product in a country, the license granted to the Company under the agreement shall become perpetual, fully paid-up, irrevocable and royalty-free in such country.
MentiNova, LLC [Member]    
Upfront license fee $ 100,000  
MentiNova, LLC [Member] | Completion Of Stage One [Member]    
Milestone payments to be paid   $ 1,200,000